10-Q: Klotho Neurosciences Reports Wider Loss, Secures Funding

Klotho Neurosciences, a pre-revenue biotech, reported significantly increased losses for Q2 2025 but bolstered its cash position through recent capital raises and achieved Orphan Drug Designation for its ALS gene therapy.

Summary

• Klotho Neurosciences, Inc. reported a net loss of $4,093,231 for the three months ended June 30, 2025, a substantial increase from $451,639 for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $6,327,213, up from $1,123,683 in the prior year period.
• Operating expenses surged to $1,892,852 for Q2 2025, compared to $395,607 in Q2 2024, driven by increased professional fees, general and administrative costs, share-based compensation, and the commencement of research and development efforts.
• Cash and cash equivalents significantly increased to $8,430,946 as of June 30, 2025, from $63,741 at December 31, 2024, primarily due to $11,889,383 in net cash provided by financing activities.
• The company remains in a pre-revenue state, with no operating revenues generated to date.
• An accumulated deficit of approximately $16.9 million was reported as of June 30, 2025.
• The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to KLTO-202 (s-KL-AAV.myo) for the treatment of ALS on July 3, 2025.
• The company entered into a sales agreement with A.G.P./Alliance Global Partners on July 3, 2025, to sell up to $50,000,000 in common stock through an at-the-market offering.
• A Form S-3 Registration Statement for up to $100,000,000 in various securities was filed on July 7, 2025, and declared effective on July 25, 2025.
• The company regained compliance with Nasdaq listing requirements on July 14, 2025, and its common stock and warrants were approved for listing on the Nasdaq Capital Market.
• A warrant exercise inducement program led to 11.0 million warrants exercised for $11.4 million in gross proceeds during Q2 2025.
• Convertible notes totaling $650,000 from Austria Capital LLC and $881,085 from 3i LP were converted into 2,600,000 and 5,413,474 common shares, respectively.
• 6,250,000 common shares were issued at $0.08 per share for $500,000 in gross proceeds on June 5, 2025.
• 500 preferred B shares were issued for $500,000 on June 9, 2025, convertible into 6,250,000 common shares.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the company successfully raised significant capital and achieved a crucial FDA designation for its lead candidate, its financial performance shows rapidly increasing losses and a 'going concern' warning. The reliance on continuous capital raises at highly dilutive terms, coupled with identified internal control weaknesses, indicates significant operational and financial instability. The positive developments provide a lifeline but do not yet offset the fundamental financial challenges.

Positives

• Secured significant financing, with net cash provided by financing activities totaling $11,889,383 for the six months ended June 30, 2025, substantially increasing cash reserves to $8,430,946.
• Achieved Orphan Drug Designation from the FDA for KLTO-202 for ALS, providing incentives like tax credits, GDUFA fee waiver, and seven years of U.S. market exclusivity.
• Regained compliance with Nasdaq listing rules regarding bid price and equity, and successfully transitioned to the Nasdaq Capital Market, maintaining its public listing.
• Successfully executed a warrant exercise inducement program, generating $11.4 million in gross proceeds from the exercise of 11.0 million warrants.
• Entered into a sales agreement for a potential $50 million at-the-market offering and filed a $100 million S-3 registration statement, indicating strong future capital raising potential.
• Established a manufacturing and development agreement with AAVnerGene Inc. for KLTO-202, leveraging specialized platform technology.

Negatives

• Experienced a significant increase in net loss, reaching $4,093,231 for Q2 2025 and $6,327,213 for H1 2025, indicating a worsening financial performance.
• Operating expenses rose sharply by $1,497,245 in Q2 2025 compared to Q2 2024, reflecting increased burn rate.
• Incurred substantial interest expense of $1,760,025 in Q2 2025 and $2,313,962 in H1 2025, a significant increase from prior periods.
• The company is in a pre-revenue state and continues to incur significant operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern without additional funding.
• Identified material weaknesses in internal control over financial reporting, including inadequate accounting resources and lack of segregation of duties, which could lead to financial misstatements.
• Experienced significant dilution from recent capital raises, including warrant exercises, note conversions, and new share issuances at low prices (e.g., $0.08 per share, $0.25 conversion prices).

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months without obtaining additional working capital funding from equity and/or debt securities.
• The company is in a pre-revenue state and requires significant cash resources to execute its development plans and continue operations, with no guarantee of future revenue generation.
• Material weaknesses in internal control over financial reporting, including inadequate accounting resources and lack of segregation of duties, pose a risk of financial misstatements.
• The company's stock price has been volatile and previously fell below Nasdaq's minimum bid price requirement, indicating potential delisting risks if compliance is not maintained.
• Future capital raises, which are necessary for continued operations, will likely result in significant dilution for existing shareholders.
• The fair value of warrant liabilities increased, indicating potential future financial obligations or volatility related to these instruments.
• The company's business plan relies on the successful development and commercialization of drug candidates, which is subject to extensive regulatory approvals, clinical trial risks, and market acceptance.

Future Outlook

The company expects net cash used in operating activities to increase in the coming periods until its products generate meaningful revenue. It is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue its development plans and operations. The company plans to use net proceeds from future offerings for working capital and general corporate purposes. It also anticipates utilizing its acquired licenses and patents later in the year. The company is actively developing its KLTO-202 gene therapy candidate for ALS, with manufacturing and development agreements in place.

Management Comments

• We expect net cash used in operating activities to increase in the coming periods, until our products are able to produce meaningful revenue.
• Management of the Company believes that these material weaknesses are due to the small size of the Company's accounting staff. The small size of the Company's accounting outsourced staff may prevent adequate controls in the future due to the cost/benefit of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.

Industry Context

Klotho Neurosciences operates in the highly capital-intensive and high-risk biotechnology sector, specifically focusing on chronic diseases including cancer, cardiovascular, and neurodegenerative disorders. The company's strategy involves both generic/biosimilar drug portfolios and proprietary gene therapy. The recent FDA Orphan Drug Designation for its ALS gene therapy candidate (KLTO-202) is a significant milestone, aligning with a broader industry trend of increasing focus on rare diseases due to regulatory incentives and unmet medical needs. However, as a pre-revenue company, it faces common biotech challenges such as substantial R&D costs, prolonged development timelines, and heavy reliance on external financing, which often leads to significant shareholder dilution.

Comparison to Industry Standards

• The company's pre-revenue status and significant operating losses are typical for early-stage biotechnology companies, similar to many small-cap biotechs like BrainStorm Cell Therapeutics (BSM) or Anavex Life Sciences (AVXL) in the neurodegenerative space, which also incur substantial R&D and G&A expenses without product sales.
• The cash burn rate, with net cash used in operating activities increasing to $3.52 million in H1 2025, is high but not uncommon for a biotech advancing its pipeline. For example, companies like Voyager Therapeutics (VYGR) or uniQure (QURE), also in gene therapy, typically report higher quarterly cash burn rates in the tens of millions as they progress through clinical trials.
• The FDA Orphan Drug Designation for KLTO-202 for ALS is a critical regulatory achievement, comparable to designations received by companies like Amylyx Pharmaceuticals for AMX0035 in ALS, which provided market exclusivity and facilitated development. This designation is a positive signal for the potential marketability and regulatory pathway of the drug.
• The capital raises, including warrant exercises and convertible note conversions, are standard financing mechanisms for pre-revenue biotechs. However, the low share prices ($0.08 per share, $0.25 conversion prices) at which some capital was raised indicate a high degree of dilution and potentially a distressed valuation, which is more severe than typical early-stage funding rounds for well-capitalized peers.
• The Nasdaq compliance issues (bid price, MVPHS, MVLS) and subsequent move to the Nasdaq Capital Market are indicative of financial and operational challenges, which are not standard for established, healthy public companies. This situation is more akin to smaller, struggling biotechs that face delisting threats, unlike larger, more stable companies such as Biogen (BIIB) or Eli Lilly (LLY).

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various legal proceedings and claims that arise in the ordinary course of business, but management does not believe any will have a material effect on the company's business, financial condition, results of operations, or cash flows.

Related Party Transactions

• On December 12, 2023, the company issued a promissory note to a member of management, which accrued a one-time interest fee of $2,460 and was paid off in full as of June 30, 2025.
• As of June 30, 2025, the aggregate related party payable was $0, down from $31,000 at December 31, 2024.

Stakeholder Impact

• **Shareholders**: Face significant dilution from ongoing capital raises (warrant exercises, note conversions, new share issuances at low prices) but benefit from increased cash reserves and the FDA Orphan Drug Designation, which could enhance long-term value if the drug is successful. The Nasdaq compliance ensures continued market access.
• **Employees**: Benefit from the company's continued operations and strategic advancements, including new employment agreements for key executives and equity incentive plans designed for retention.
• **Creditors**: Notes payable to related parties and other notes have been paid off or converted, reducing immediate debt obligations, but the company's 'going concern' warning indicates ongoing financial risk.
• **Customers (Future)**: The FDA Orphan Drug Designation for ALS could lead to a new treatment option for patients with this severe neurodegenerative disease, potentially addressing an unmet medical need.
• **Regulatory Authorities**: The company has successfully addressed Nasdaq listing deficiencies and received a key FDA designation, demonstrating engagement with regulatory requirements.

Next Steps

• Obtain additional working capital funding from the sale of equity and/or debt securities to continue development plans and operations.
• Increase the number of employees to implement adequate segregation of duties within the internal control framework as the company grows.
• Utilize acquired licenses and patents later in the year.
• Continue development and manufacturing of KLTO-202 gene therapy candidate for ALS with AAVnerGene Inc.
• Potentially offer and sell shares of common stock through the $50,000,000 at-the-market offering with A.G.P.
• Potentially offer and sell up to $100,000,000 in various securities under the effective Form S-3 Registration Statement.
• Continue to monitor and address internal control deficiencies as the company grows.

Key Dates

Recommendation

While Klotho Neurosciences reported significantly wider losses and carries a 'going concern' warning, the recent successful capital raises, including a $50 million ATM facility and a $100 million S-3 registration, provide a critical lifeline. The FDA Orphan Drug Designation for its ALS gene therapy (KLTO-202) is a substantial positive catalyst, offering market exclusivity and development incentives. However, the company remains pre-revenue with a high cash burn and identified internal control weaknesses. For a seasoned investor, the stock is highly speculative. A 'Hold' recommendation is appropriate for existing shareholders, acknowledging the significant risks but also the potential upside from the recent regulatory and financing achievements. New investors should exercise extreme caution due to the high risk profile and consider waiting for further clinical and financial milestones.

Keywords

Biotechnology, Neurodegenerative diseases, ALS, Orphan Drug Designation, Gene therapy, Cancer treatment, SEC filing, 10-Q, Financial results, Capital raise, Nasdaq compliance, Pre-revenue, Going concern, Drug development